Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Advanced Solid Tumor
Clinical trial register · Japan

Advanced Solid Tumor Trials in Japan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2516 matching records held by the registry are in this view. Synced 12 Nov 2026, 03:19 UTC
2516
Studies in scope
all four open statuses
1285
Recruiting now
open to new participants
352
Lead sponsors
across recruiting studies
Top sites
Kashiwa 11 Chūōku 9 Osaka 6 Nagoya 6 Kōtoku 5

Advanced Solid Tumor trials in Japan

22 of 2516 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
First-in-Human Trial of DS1025a in Participants With Advanced Solid Tumors
NCT07681882Advanced Solid Tumor, Metastatic Solid Tumor, Unresectable Solid Tumor
Daiichi Sankyo
Phase 1
45
Kashiwa, Osaka, Tokyo
2026-08-06
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 1
77
Chūōku
2025-10-10
Recruiting
Daiichi Sankyo
Phase 1
192
Kashiwa, Kōtoku
2025-10-02
Recruiting
China-Japan Friendship Hospital
Phase 1/2
38
2025-08-01
Recruiting
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
NCT06997029Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer
Bristol-Myers Squibb
Phase 1
234
Kashiwa, Hirakata, Chuo-ku, Koto-ku
2025-08-01
Active, closed
Daiichi Sankyo
Phase 2
335
Akashi, Chūōku, Fukuoka, Hidaka, Kashiwa, Kōtoku, Nagoya, Osaka
2025-01-06
Recruiting
Anti-GD2 ADC M3554 in Advanced Solid Tumors
NCT06641908Advanced Solid Tumor
EMD Serono Research & Development Institute, Inc.
Phase 1
65
Chūōku
2024-11-08
Active, closed
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
Eli Lilly and Company
Phase 1
750
Chiba, Kyoto, Shizuoka, Tokyo
2024-10-21
Active, closed
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
NCT06561685Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
Eli Lilly and Company
Phase 1
340
Chūōku, Kashiwa, Kōtō City, Nagaizumi-cho,Sunto-gun
2024-09-19
Active, closed
EMD Serono Research & Development Institute, Inc.
Phase 1
60
Fukuoka, Kashiwa-shi, Kōtoku, Kumamoto
2024-08-07
Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
460
Chūōku, Kashiwa, Chiba, Kōtō City, Nagoya
2024-07-01
Active, closed
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
NCT06238479Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
490
Chūōku, Kashiwa, Kōtō City, Kyoto
2024-03-05
Recruiting
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
Daiichi Sankyo
Phase 2
740
Hidaka, Kagoshima, Kanagawa, Kashiwa-shi, Matsuyama, Nagaizumi-cho, Nagoya, Osakasayama-shi
2024-02-26
Active, closed
Daiichi Sankyo
Phase 1
210
Chūōku, Fukuoka, Kashiwa, Kōtoku, Nagoya, Osaka, Ōsaka-sayama, Shizuoka
2024-02-22
Active, closed
A Study of KK2269 in Adult Participants With Solid Tumors
NCT06266299Advanced Solid Tumor, Metastatic Solid Tumor, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Kyowa Kirin Co., Ltd.
Phase 1
83
Nagoya, Toyoake, Kashiwa, Matsuyama, Kurume, Kobe, Yokohama, Hirakata
2024-01-18
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
BeOne Medicines
Phase 1
433
Nagoya, Kashiwa, Suntogun
2023-12-01
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
NCT05875168Advanced Solid Tumor, Metastatic Solid Tumor
Daiichi Sankyo
Phase 1/2
590
Chūōku, Hirakata-shi, Kashiwa, Kōtoku, Kumamoto, Osaka, Ōsaka-sayama, Sapporo
2023-08-18
Recruiting
Daiichi Sankyo
Phase 1
128
Gifu, Nakatogari, Osaka, Tokyo
2023-05-30
Recruiting
Betta Pharmaceuticals Co., Ltd.
Phase 1
82
2023-04-24
Active, closed
Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors
NCT05101096Advanced Solid Tumor, Metastatic Triple-Negative Breast Cancer, HR+/HER2- Metastatic Breast Cancer, Metastatic Urothelial Cancer
Gilead Sciences
Phase 1/2
135
Aichi, Akita, Aoba-ku, Aomori, Asahi-ku, Bunkyō City, Chiba, Chūōku
2021-10-20
Active, closed
Daiichi Sankyo
Phase 1/2
247
Aichi, Chiba, Hokkaido, Hyōgo, Kagawa, Osaka, Ōsaka-sayama, Saitama
2019-11-03
Rows per page Showing 1–22 of 22
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 November 2026. https://priyalifescience.com/clinical-trials-japan/condition/advanced-solid-tumor

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,516 studies in total at the last sync on 12 Nov 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 22 of those studies listing the condition Advanced Solid Tumor.

How many Advanced Solid Tumor trials are recruiting in Japan?

13 of the 22 studies on this page are recruiting new participants as of the 12 Nov 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 9 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Advanced Solid Tumor), 22 studies
PhaseStudiesRecruitingShare
Phase 1161072.7%
Phase 1/24218.2%
Phase 2219.1%

Most active sponsors

Lead sponsors with the most studies (Advanced Solid Tumor)
Lead sponsorStudiesRecruiting
Daiichi Sankyo85
Eli Lilly and Company41
EMD Serono Research & Development Institute, Inc.32
BeOne Medicines22
Betta Pharmaceuticals Co., Ltd.11
Bristol-Myers Squibb11
China-Japan Friendship Hospital11
Gilead Sciences10
Kyowa Kirin Co., Ltd.10
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.